B. Riley Equities Analysts Decrease Earnings Estimates for Uniqure NV (QURE)

Uniqure NV (NASDAQ:QURE) – B. Riley reduced their Q3 2018 earnings estimates for shares of Uniqure in a research note issued on Thursday, August 9th. B. Riley analyst M. Kumar now anticipates that the biotechnology company will earn ($0.58) per share for the quarter, down from their prior forecast of ($0.53). B. Riley currently has a “Buy” rating and a $50.00 target price on the stock. B. Riley also issued estimates for Uniqure’s Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($2.22) EPS, Q1 2019 earnings at ($0.67) EPS, Q2 2019 earnings at ($0.67) EPS, Q3 2019 earnings at ($0.67) EPS, Q4 2019 earnings at ($0.67) EPS, FY2019 earnings at ($2.67) EPS, FY2020 earnings at ($3.88) EPS, FY2021 earnings at $0.10 EPS and FY2022 earnings at $1.29 EPS.

Uniqure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.04. The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.37 million. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%.

QURE has been the subject of a number of other research reports. HC Wainwright set a $35.00 price objective on shares of Uniqure and gave the company a “buy” rating in a report on Tuesday, May 1st. Leerink Swann restated an “outperform” rating and issued a $63.00 price objective (up previously from $26.00) on shares of Uniqure in a report on Monday, May 7th. Wells Fargo & Co began coverage on shares of Uniqure in a report on Wednesday, May 16th. They issued an “outperform” rating and a $47.00 price objective for the company. BidaskClub upgraded shares of Uniqure from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, ValuEngine upgraded shares of Uniqure from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $44.89.

Shares of Uniqure opened at $35.31 on Monday, MarketBeat reports. The company has a quick ratio of 5.48, a current ratio of 8.36 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $1.29 billion, a P/E ratio of -12.01 and a beta of 0.05. Uniqure has a fifty-two week low of $7.52 and a fifty-two week high of $40.99.

Institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP lifted its stake in Uniqure by 3,972.6% in the first quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,363 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in Uniqure by 276.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 4,700 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in Uniqure in the first quarter worth approximately $177,000. Gagnon Securities LLC purchased a new position in Uniqure in the second quarter worth approximately $209,000. Finally, Jane Street Group LLC purchased a new position in Uniqure in the first quarter worth approximately $224,000. Institutional investors own 44.07% of the company’s stock.

In related news, insider Steven Zelenkofske sold 23,929 shares of Uniqure stock in a transaction that occurred on Wednesday, June 6th. The shares were sold at an average price of $37.14, for a total value of $888,723.06. Following the completion of the transaction, the insider now owns 159,458 shares in the company, valued at $5,922,270.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.99% of the stock is owned by insiders.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Story: Dividend

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply